Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape

Immune checkpoint (IC) inhibition in glioblastoma (GBM) has not shown promising results in the last decade compared to other solid tumors. Several factors contributing to the lack of immunotherapy response include the profound immunosuppressive nature of GBM, highly redundant signaling pathways unde...

全面介紹

書目詳細資料
發表在:Frontiers in Immunology
Main Authors: Julio F. Inocencio, Stefan Mitrasinovic, Mohammad Asad, Ian F. Parney, Xingxing Zang, Benjamin T. Himes
格式: Article
語言:英语
出版: Frontiers Media S.A. 2024-09-01
主題:
在線閱讀:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1424396/full
_version_ 1850068450039300096
author Julio F. Inocencio
Stefan Mitrasinovic
Mohammad Asad
Ian F. Parney
Ian F. Parney
Xingxing Zang
Xingxing Zang
Benjamin T. Himes
Benjamin T. Himes
author_facet Julio F. Inocencio
Stefan Mitrasinovic
Mohammad Asad
Ian F. Parney
Ian F. Parney
Xingxing Zang
Xingxing Zang
Benjamin T. Himes
Benjamin T. Himes
author_sort Julio F. Inocencio
collection DOAJ
container_title Frontiers in Immunology
description Immune checkpoint (IC) inhibition in glioblastoma (GBM) has not shown promising results in the last decade compared to other solid tumors. Several factors contributing to the lack of immunotherapy response include the profound immunosuppressive nature of GBM, highly redundant signaling pathways underlying immune checkpoints, and the negative immunogenic impact of current standard of care on the tumor microenvironment. In this review, we will discuss various ICs in the context of GBM, their interplay with the tumor immune microenvironment, relevant pre-clinical and clinical studies, and the impact of current treatment modalities on GBM IC blockade therapy. Understanding the molecular mechanisms that drive ICs, and how they contribute to an immunosuppressive tumor microenvironment is critical in advancing IC inhibition therapy in GBM. Furthermore, revisiting current treatment modalities and their impact on the immune landscape is instrumental in designing future combinatorial therapies that may overcome treatment resistance.
format Article
id doaj-art-d88b8cd80c534ebc81fe4e751ea86ec8
institution Directory of Open Access Journals
issn 1664-3224
language English
publishDate 2024-09-01
publisher Frontiers Media S.A.
record_format Article
spelling doaj-art-d88b8cd80c534ebc81fe4e751ea86ec82025-08-20T00:18:25ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-09-011510.3389/fimmu.2024.14243961424396Immune checkpoint pathways in glioblastoma: a diverse and evolving landscapeJulio F. Inocencio0Stefan Mitrasinovic1Mohammad Asad2Ian F. Parney3Ian F. Parney4Xingxing Zang5Xingxing Zang6Benjamin T. Himes7Benjamin T. Himes8Department of Neurological Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, United StatesDepartment of Neurological Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, United StatesDepartment of Neurological Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, United StatesDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, United StatesDepartment of Immunology, Mayo Clinic, Rochester, MN, United StatesDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United StatesDepartment of Oncology, Albert Einstein College of Medicine, Bronx, NY, United StatesDepartment of Neurological Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, United StatesDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United StatesImmune checkpoint (IC) inhibition in glioblastoma (GBM) has not shown promising results in the last decade compared to other solid tumors. Several factors contributing to the lack of immunotherapy response include the profound immunosuppressive nature of GBM, highly redundant signaling pathways underlying immune checkpoints, and the negative immunogenic impact of current standard of care on the tumor microenvironment. In this review, we will discuss various ICs in the context of GBM, their interplay with the tumor immune microenvironment, relevant pre-clinical and clinical studies, and the impact of current treatment modalities on GBM IC blockade therapy. Understanding the molecular mechanisms that drive ICs, and how they contribute to an immunosuppressive tumor microenvironment is critical in advancing IC inhibition therapy in GBM. Furthermore, revisiting current treatment modalities and their impact on the immune landscape is instrumental in designing future combinatorial therapies that may overcome treatment resistance.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1424396/fullimmune checkpointsglioblastomaimmune microenvironmenttumor immunosuppressionimmunotherapy
spellingShingle Julio F. Inocencio
Stefan Mitrasinovic
Mohammad Asad
Ian F. Parney
Ian F. Parney
Xingxing Zang
Xingxing Zang
Benjamin T. Himes
Benjamin T. Himes
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape
immune checkpoints
glioblastoma
immune microenvironment
tumor immunosuppression
immunotherapy
title Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape
title_full Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape
title_fullStr Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape
title_full_unstemmed Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape
title_short Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape
title_sort immune checkpoint pathways in glioblastoma a diverse and evolving landscape
topic immune checkpoints
glioblastoma
immune microenvironment
tumor immunosuppression
immunotherapy
url https://www.frontiersin.org/articles/10.3389/fimmu.2024.1424396/full
work_keys_str_mv AT juliofinocencio immunecheckpointpathwaysinglioblastomaadiverseandevolvinglandscape
AT stefanmitrasinovic immunecheckpointpathwaysinglioblastomaadiverseandevolvinglandscape
AT mohammadasad immunecheckpointpathwaysinglioblastomaadiverseandevolvinglandscape
AT ianfparney immunecheckpointpathwaysinglioblastomaadiverseandevolvinglandscape
AT ianfparney immunecheckpointpathwaysinglioblastomaadiverseandevolvinglandscape
AT xingxingzang immunecheckpointpathwaysinglioblastomaadiverseandevolvinglandscape
AT xingxingzang immunecheckpointpathwaysinglioblastomaadiverseandevolvinglandscape
AT benjaminthimes immunecheckpointpathwaysinglioblastomaadiverseandevolvinglandscape
AT benjaminthimes immunecheckpointpathwaysinglioblastomaadiverseandevolvinglandscape